Quidel Moves Beyond Point-Of-Care Focus With Diagnostic Hybrids Buy
This article was originally published in The Gray Sheet
Executive Summary
Point-of-care-testing firm Quidel hopes to greatly expand its hospital and reference laboratory customer base, and become less reliant on flu season revenues, with its $130 million acquisition of Diagnostic Hybrids
You may also be interested in...
As Flu Season Approaches, Quidel Looks To Avoid Prior Pitfalls
Rapid diagnostics maker Quidel is tweaking its business strategy to smooth out its balance sheet based on lessons learned from unpredictable flu seasons and this year's outbreak of the novel H1N1 strain
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.